BPC-157: research

An experimental repair peptide with mostly animal evidence and a few small human reports.

Also called: BPC 157, BPC157, Body protection compound 157, Bepecin, PL-14736, PCO-02.

Healing and repair peptides · Experimental synthetic pentadecapeptide.

Six distinct clinical reports have results, including two abstract-only enema trials. Four registry records have no posted results; long-term benefit and safety remain unknown.

Studies

BPC-157 dosage

Typical reported dose: 200–250 mcg once a day

  • IV pilot: 10 mg then 20 mg: Day 1: 10 mg; day 2: 20 mg, each in 250 mL normal saline over 1 hour. once daily on two consecutive days, into a vein. Studied in a trial. Studied in: Two previously exposed adults in the 2025 safety pilot. (source)
  • Under-skin daily reports: Reports and forum advice span 100-400+ mcg daily; 200-250 mcg is called average in this thread. once daily, under the skin. Reported by users, common report. Studied in: Adults reporting use online. (source)
  • 250 to 500 mcg twice daily: 250 mcg twice daily for the first two weeks., then 500 mcg twice daily from week 3 through the reported seven-week course. twice daily, under the skin. Reported by users, common report. Studied in: Adults reporting use online. (source)
  • Muscle-injection step-down report: 750 mcg twice daily for 1-2 weeks, then 250 mcg twice daily. twice daily, into muscle. Reported by users, rare report. Studied in: Adults reporting use online. (source)
  • Oral report: two 30-day steps: Days 1-30: 250 mcg twice daily. Days 31-60: 500 mcg twice daily. twice daily, by mouth. Reported by users, occasional report. Studied in: Adults reporting use online. (source)
  • Oral 500 mcg at night: 500 mcg orally at night. once daily at night, by mouth. Reported by users, occasional report. Studied in: Adults reporting use online. (source)

Highest studied: 20 mg IV over one hour on day 2 in two adults; no repeated-course safety evidence..

These are doses reported in labels, trials or user reports, not a personal plan. Check the source behind each one.

Work out syringe units with the dosing calculator

BPC-157 side effects and risks

Reported side effects

  • Headache and gas: Most frequent events in the enema phase 1 abstract; rates were not reported. No obvious placebo difference., mild (source)
  • Injection-site redness or swelling: One FDA injection report described nine days of redness and swelling; another peptide was also used., moderate. Seek review if worsening, hot or painful, or accompanied by fever. (source)
  • Shortness of breath: One FDA report led to an emergency visit. Timing and other medicines were not detailed., serious. Stop use and seek urgent care; causality is not established. (source)
  • Skin or gum darkening with a blend: One BPC 157/TB 500 report recurred after restarting. The responsible ingredient is unknown., moderate. Stop the blend and have the change assessed. (source)
  • Anxiety or loss of pleasure: Forum reports only; no denominator or proven cause., moderate. Stop use and seek assessment for new or persistent mood changes. (source)
  • Nausea, fatigue or stomach upset: Oral users describe these symptoms; rates and product contents are unknown., mild. Review persistent symptoms; do not assume they show healing or detox. (source)
  • Nasal dryness or postnasal drip: Reported by a nasal blend user; no incidence estimate., mild (source)

Stop and get help if

  • Trouble breathing, throat swelling, collapse or fainting after a dose: Stop use and call emergency services now.
  • Fever with a hot, spreading injection-site reaction, confusion or very fast breathing: Seek urgent care now; call emergency services for confusion or breathing trouble.
  • New chest pain, severe palpitations or sudden vision loss: Stop use and get urgent medical assessment.
  • New severe depression or thoughts of self-harm: Stop use and seek urgent mental-health help; use emergency services if there is immediate danger.

Who should avoid it

  • pregnant: No human pregnancy safety data. Block as a precaution; animal findings do not establish fetal safety.
  • breastfeeding: No human milk-transfer or infant safety data. Block as a precaution.
  • tryingToConceive: No adequate human fertility or early-pregnancy safety data. Block as a precaution.
  • under18: No pediatric dose or safety study found. Block use in minors.
  • activeCancer: Lab studies promote blood-vessel growth. Block as a precaution; cancer promotion in humans has not been established.
  • cancerHistory: Blood-vessel growth raises a theoretical concern. Review cancer history with the treating team; recurrence risk is unknown.
  • other: Avoid a product that previously caused a severe allergic reaction; impurities and inactive ingredients can matter.
  • kidneyDisease: Human exposure and clearance in kidney disease are unknown; the two-person IV pilot cannot settle this.
  • liverDisease: No dosing or safety study in people with liver disease was found.
  • heartCondition: Human artery tissue relaxed in the lab. Whole-body blood-pressure and heart effects remain uncertain.
  • uncontrolledBloodPressure: Effects on blood pressure are not established in patients. The vessel-signaling findings warrant review.
  • bleedingDisorder: Needle procedures can cause bruising or bleeding; BPC-157 effects on human clotting are unknown.
  • psychiatricCondition: Users report anxiety, low mood and loss of pleasure. Causality and frequency are unknown.
  • surgeryPlanned: Tell the surgical team about use and blends. There is no validated preoperative stopping interval.
  • testedAthlete: WADA 2026 explicitly prohibits BPC-157 at all times under S0, including outside competition.

Interactions

  • Anticoagulants and antiplatelet medicines: Needle procedures can increase bruising or bleeding. A direct BPC-157 drug interaction has not been measured.
  • Blood-pressure medicines, nitrates and PDE5 inhibitors: Additive low blood pressure is theoretical from artery-tissue relaxation. No clinical interaction study confirms it.
  • TB-500 and other experimental repair peptides: Human safety of these stacks is unknown. A blend-related FDA report cannot identify the responsible peptide.
  • Insulin and sulfonylureas: No BPC-specific low-blood-sugar interaction is established. Normal glucose in two IV users cannot exclude an interaction.

Product quality risks

  • A 2026 preprint found 17 BPC-157 test reports without the stated peptide, a reported identity-failure rate of 3.5%.
  • That preprint found median BPC-157 content of 103.50% of label, IQR 94.20%-115.10%; the samples were not a random market survey.
  • Across all peptides, 15% of 243 endotoxin-tested samples had measurable endotoxin; this is not a BPC-specific rate.
  • FDA identifies peptide impurities, aggregates and unclear ingredient identity as safety concerns.
  • Health Canada seized unauthorized BPC-157 injections and recalled unauthorized raw powder; these actions do not measure every vial.
  • FDA issued an October 23, 2020 warning about BPC-157 products with COVID-19 claims; corrective status did not mean approval.

How BPC-157 works

In lab and animal work, it changes signals involved in blood-vessel growth, cell movement and injury repair. These effects may explain animal healing results. They do not prove that it repairs human injuries.

  • VEGFR2-Akt-eNOS: Increases blood-vessel growth signals in cells and animals.
  • FBXO22 and BACH1: A 2026 cell study proposes that BPC157 stabilizes BACH1 and promotes vessel-cell growth.
  • FAK and paxillin: Changes cell movement and tendon-cell survival in lab models.
  • Growth hormone receptor: Raises receptor expression in rat tendon cells; this does not show a rise in human growth hormone.

Half-life: Human half-life is unknown. Less than 30 minutes was measured in rats and dogs.

Gaps: No full controlled efficacy paper or reliable long-term human safety estimate was found. Daily oral, under-skin, muscle and nasal schedules lack published dose-finding or absorption results. The completed oral-gummy registry has no posted results; the 2015 oral trial status is unknown. Historical enema trials exist only as abstracts summarized by FDA; detailed methods and arm rates are missing. Human pregnancy, breastfeeding, fertility, cancer and pediatric safety remain unknown. No validated interaction, microdose, cycling, titration or washout schedule was found. Community prevalence bands are qualitative, not measured population frequencies. No route-matched published ceiling exists for community schedules, so aboveStudied cannot be calculated. The schema lacks rectal, joint, bladder-wall and submucosal routes; their doses remain in study arms. IV safety results do not establish an IV half-life or an oral-to-injected dose conversion. FDA vote minutes were not located; the 8-6-1 tally is press-reported, and the final bulks lists still omit BPC-157. Six-week bladder follow-up is described in an indexed review; the full primary paper was not retrievable from this server.

Related to BPC-157

BPC-157: the short version

Sources

Sources checked: 2026-10-18.

Information only, not medical advice. Peptifacts does not sell anything and does not link to sellers.